

**UNITED STATES BANKRUPTCY COURT
SOUTHERN DISTRICT OF NEW YORK**

In re:

PURDUE PHARMA L.P., *et al.*,

Debtors.¹

Chapter 11

Case No. 19-23649 (RDD)

(Jointly Administered)

**TWENTY FOURTH MONTHLY FEE STATEMENT OF FTI CONSULTING, INC. FOR
COMPENSATION FOR SERVICES RENDERED AND REIMBURSEMENT OF
EXPENSES INCURRED AS FINANCIAL ADVISOR TO THE AD HOC COMMITTEE
OF GOVERNMENTAL AND OTHER CONTINGENT LITIGATION CLAIMANTS FOR
THE PERIOD FROM SEPTEMBER 1, 2021 THROUGH SEPTEMBER 30, 2021**

Name of Applicant:	FTI Consulting, Inc.
Authorized to provide Professional Services to:	Ad Hoc Committee of Governmental and Other Contingent Litigation Claimants
Date of Order Approving Debtors' Payment of Fees and Expenses of Applicant:	December 2, 2019 [ECF No. 553]
Period for which compensation and reimbursement is sought:	September 1, 2021 through September 30, 2021
Monthly Fees Incurred:	\$244,958.50

1. The Debtors in these chapter 11 cases, along with the last four digits of each Debtor's registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifesciences Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF LP (0495), SVC Pharma LP (5717), and SVC Pharma Inc. (4014). The Debtors' corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

Monthly Expenses Incurred: \$0.00

Total Fees and Expenses Due: \$244,958.50

This is a: X monthly _____interim _____final application

PRIOR APPLICATIONS:

Docket No./Filed	Compensation Period	Requested		Approved	
		Fees	Expenses	Fees	Expenses
Docket No. 635 Filed On 12/9/2019	9/19/2019 – 10/31/2019	\$778,791.50	\$680.61	\$771,291.50	\$680.61
Docket No. 741 Filed On 1/13/2020	11/1/2019 – 11/30/2019	\$827,575.00	\$899.41	\$820,075.00	\$899.41
Docket No. 852 Filed on 2/20/2020	12/1/2019 – 12/31/2019	\$802,036.50	\$2,284.19	\$794,536.50	\$2,284.19
Docket No. 916 Filed on 3/12/2020	1/1/2020 – 1/31/2020	\$774,662.00	\$11,530.84	\$767,162.00	\$11,530.84
Docket No. 1090 Filed on 4/27/2020	2/1/2020 – 2/29/2020	\$615,089.00	\$6,141.22	\$610,714.00	\$6,141.22
Docket No. 1171 Filed on 5/19/2020	3/1/2020 – 3/31/2020	\$561,863.50	\$67.08	\$557,488.50	\$67.08
Docket No. 1251 Filed on 6/10/2020	4/1/2020 – 4/30/2020	\$428,303.00	\$1,732.28	\$423,928.00	\$1,732.28
Docket No. 1379 Filed on 7/13/2020	5/1/2020 – 5/31/2020	\$303,367.00	\$4,325.26	\$298,992.00	\$4,325.26
Docket No. 1651 Filed on 9/2/2020	6/1/2020 – 6/30/2020	\$374,753.00	\$96.90	\$372,253.00	\$ 96.90
Docket No. 1725 Filed on 9/25/2020	7/1/2020 – 7/31/2020	\$446,975.50	\$0.00	\$444,475.50	\$0.00
Docket No. 1850 Filed on 10/26/2020	8/1/2020 – 8/31/2020	\$261,092.00	\$108.25	\$258,592.00	\$108.25
Docket No. 1950 Filed on 10/26/2020	9/1/2020 – 9/30/2020	\$357,546.50	\$0.00	\$355,046.50	\$0.00
Docket No. 2031 Filed on 11/24/2020	9/19/2019 – 9/30/2020	\$44,462.00	\$0.00	\$41,462.60	\$0.00
Docket No. 2154 Filed on 12/18/2020	10/1/2020 – 10/31/2020	\$356,078.50	\$0.00	\$353,078.50	\$0.00
Docket No. 2308 Filed on 1/20/2021	11/1/2020 – 11/30/2020	\$450,827.00	\$0.00	\$447,827.00	\$0.00
Docket No. 2503 Filed on 3/17/2021	12/1/2020 – 12/31/2020	\$308,146.00	\$0.00	\$305,146.00	\$0.00
Docket No. 2504 Filed on 3/17/2021	1/1/2021 – 1/31/2021	\$493,773.50	\$0.00	\$490,773.50	\$0.00
Docket No. 2848 Filed on 5/12/2021	2/1/2021 – 2/28/2021	\$381,199.00	\$9.99	\$377,458.99	\$9.99
Docket No. 2849 Filed on 5/12/2021	3/1/2021 – 3/31/2021	\$513,645.00	\$0.00	\$509,895.00	\$0.00
Docket No. 3017 Filed on 6/11/2021	4/1/2021 – 4/30/2021	\$415,904.00	\$0.00	\$412,154.00	\$0.00
Docket No. 3225 Filed on 7/15/2021	5/1/2021 – 5/31/2021	\$363,711.00	\$40.00	\$360,001.00	\$40.00
Docket No. 3747 Filed on 9/9/2021	6/1/2021 – 6/30/2021	\$303,427.00	\$0.00	\$242,741.60	\$0.00
Docket No. 3798 Filed on 9/21/2021	7/1/2021 – 7/31/2021	\$431,630.50	\$135.81	\$345,304.40	\$135.81
Docket No. 3941 Filed on 10/14/2021	8/1/2021 – 8/31/2021	\$284,159.00	\$20.94	\$0.00	\$0.00

Note: The fee examiner's agreed upon reductions of \$30,000, \$17,500, \$10,000, \$15,000, and \$15,000 were allocated evenly across fees from the first, second, third, fourth, and fifth interim period, respectively.

This statement (the “**Fee Statement**”) of FTI Consulting, Inc. (together with its wholly owned subsidiaries and independent contractors, “**FTI**”) as financial advisor to the Ad Hoc Committee of Governmental and Other Contingent Litigation Claimants of Purdue Pharma L.P., *et al.* (the “**Committee**”) is submitted in accordance with the *Order Establishing Procedures for Interim Compensation and Reimbursement of Expenses for Retained Professionals* [ECF No. 529] and the *Order Authorizing the Debtors to Assume the Reimbursement Agreement and Pay the Fees and Expenses of the Ad Hoc Committee’s Professionals* [ECF No. 553] entered on November 21, 2019 and December 2, 2019, respectively, (the “**Orders**”). In support of this Fee Statement, FTI respectfully states as follows.

1. The fees and expenses for the period from September 1, 2021 through and including September 30, 2021 (the “**Fee Period**”) amount to:

Professional Fees	\$244,958.50
Expenses	<u>0.00</u>
TOTAL	<u>\$244,958.50</u>

2. If no timely and proper objection is made by a party-in-interest within fourteen (14) days after service of this Fee Statement, the Debtors are authorized to pay 80% of professional fees and 100% of out-of-pocket expenses. These amounts are presented below.

Professional Fees at 80%	\$195,966.80
Expenses at 100%	<u>0.00</u>
TOTAL	<u>\$195,966.80</u>

3. The professionals providing services, hourly billing rates, the aggregate hours worked by each professional, and the aggregate hourly fees for each professional during the Fee Period are set forth on the schedule annexed hereto as **Exhibit “A”**.
4. A summary of aggregate hours worked and aggregate hourly fees for each task code during the Fee Period is set forth on the schedule annexed hereto as **Exhibit “B”**.

5. Detailed time entry by task code during the Fee Period is set forth on the schedule annexed hereto as **Exhibit “C”**.
6. FTI reserves the right to request, in subsequent fee statements and applications, reimbursement of any additional expenses incurred during the Fee Period, as such expenses may not have been captured to date in FTI’s billing system.

NOTICE AND OBJECTION PROCEDURES

7. Objections to this Fee Statement, if any, must be filed with the Court and served upon the Notice Parties so as to be received no later than November 25, 2021 (the **“Objection Deadline”**), setting forth the nature of the objection and the amount of fees or expenses at issue (an **“Objection”**).
8. If no objections to this Fee Statement are filed and served as set forth above, the Debtors shall promptly pay eighty percent (80%) of the fees and one hundred percent (100%) of the expenses identified herein.
9. If an objection to this Fee Statement is received on or before the Objection Deadline, the Debtors shall withhold payment of that portion of this Fee Statement to which the objection is directed and promptly pay the remainder of the fees and disbursements in the percentages set forth above. To the extent such an objection is not resolved, it shall be preserved and scheduled for consideration at the next interim fee application hearing to be heard by the Court.

Dated: New York, New York
November 11, 2021

FTI CONSULTING, INC.
Financial Advisors to the Ad Hoc Committee of
Governmental and Other Contingent Litigation
Claimants of Purdue Pharma L.P.

By: /s/ Matthew Diaz
Matthew Diaz, Senior Managing Director
Three Times Square, 10th Floor
New York, New York 10036
Telephone: (212) 499-3611
Email: matt.diaz@fticonsulting.com

EXHIBIT A**PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649****SUMMARY OF HOURS BY PROFESSIONAL****FOR THE PERIOD SEPTEMBER 1, 2021 TO SEPTEMBER 30, 2021**

Professional	Position	Specialty	Billing Rate	Total Hours	Total Fees
Diaz, Matthew	Sr Managing Director	Restructuring	1,120	49.0	\$ 54,880.00
Joffe, Steven	Sr Managing Director	Tax	1,165	0.5	582.50
Simms, Steven	Sr Managing Director	Restructuring	1,295	9.6	12,432.00
Shafer, Patterson	Managing Dir	Healthcare	600	19.5	11,700.00
Bromberg, Brian	Sr Director	Restructuring	850	67.1	57,035.00
Whitman, Andrew	Sr Director	Insurance	675	1.2	810.00
Johnson, Ancy	Director	Healthcare	475	36.5	17,337.50
Baron, Genevieve	Sr Consultant	Healthcare	375	70.0	26,250.00
Knaak, Meredith	Sr Consultant	Healthcare	375	28.5	10,687.50
Kurtz, Emma	Sr Consultant	Restructuring	580	61.6	35,728.00
Turner, Ian	Sr Consultant	Restructuring	580	29.7	17,226.00
Hellmund-Mora, Marili	Associate	Restructuring	290	1.0	290.00
GRAND TOTAL				374.2	\$ 244,958.50

EXHIBIT B**PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649****SUMMARY OF HOURS BY TASK****FOR THE PERIOD SEPTEMBER 1, 2021 TO SEPTEMBER 30, 2021**

Task Code	Task Description	Total Hours	Total Fees
1	Current Operating Results & Events	10.4	\$ 7,166.00
6	Asset Sales	4.9	4,354.00
7	Analysis of Domestic Business Plan	162.2	73,870.00
9	Analysis of Employee Comp Programs	1.3	1,456.00
10	Analysis of Tax Issues	0.5	582.50
11	Prepare for and Attend Court Hearings	10.7	12,093.50
16	Analysis, Negotiate and Form of POR & DS	14.9	15,032.00
19	Case Management	1.6	1,932.00
21	General Mtgs with Counsel and/or Ad Hoc Committee	0.8	680.00
22	Meetings with Other Parties	0.5	560.00
24	Preparation of Fee Application	12.0	7,912.00
26	Analysis of Insurance Programs	7.2	7,041.00
30	Emergence Preparation	147.2	112,279.50
GRAND TOTAL		374.2	\$ 244,958.50

EXHIBIT C

PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649

DETAIL OF TIME ENTRIES

FOR THE PERIOD SEPTEMBER 1, 2021 TO SEPTEMBER 30, 2021

Task Category	Date	Professional	Hours	Activity
1	9/1/2021	Kurtz, Emma	0.6	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	9/2/2021	Kurtz, Emma	0.5	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	9/7/2021	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	9/8/2021	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	9/9/2021	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	9/10/2021	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	9/13/2021	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	9/14/2021	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	9/15/2021	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	9/16/2021	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	9/17/2021	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	9/20/2021	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	9/20/2021	Kurtz, Emma	0.4	Review latest documents shared to the dataroom re: current financial and operating reporting to share with team.
1	9/21/2021	Diaz, Matthew	0.6	Review of the proposed transfer of the licensing agreement.
1	9/21/2021	Diaz, Matthew	0.9	Review July financial operating report and latest cash flow projections.
1	9/21/2021	Diaz, Matthew	0.6	Review articles on plan confirmation and related appeals.
1	9/21/2021	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	9/22/2021	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	9/23/2021	Kurtz, Emma	0.5	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	9/24/2021	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	9/27/2021	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	9/27/2021	Kurtz, Emma	0.4	Review recent dataroom uploads re: reporting to share with team.
1	9/28/2021	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	9/29/2021	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	9/30/2021	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1 Total			10.4	
6	9/15/2021	Bromberg, Brian	1.1	Review CellAct presentation re: proposed asset sale.
6	9/15/2021	Bromberg, Brian	0.6	Send questions on CellAct agreement.
6	9/15/2021	Diaz, Matthew	0.3	Review proposed asset purchase agreement.
6	9/16/2021	Bromberg, Brian	0.4	Review CellAct presentation and related news.
6	9/17/2021	Bromberg, Brian	0.7	Review responses and APA on CellAct.
6	9/20/2021	Bromberg, Brian	0.5	Review Debtors' responses to questions re: CellAct.
6	9/21/2021	Bromberg, Brian	0.4	Discuss CellAct proposed sale with Houlihan.
6	9/29/2021	Diaz, Matthew	0.4	Review of the proposed asset transfer.
6	9/30/2021	Bromberg, Brian	0.5	Review CellAct summary to prepare revisions.
6 Total			4.9	
7	9/1/2021	Baron, Genevieve	0.6	Attend call with internal team to discuss cost savings analysis.
7	9/1/2021	Baron, Genevieve	2.4	Analyze third party spend data for cost savings report.

EXHIBIT C

PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649

DETAIL OF TIME ENTRIES

FOR THE PERIOD SEPTEMBER 1, 2021 TO SEPTEMBER 30, 2021

Task Category	Date	Professional	Hours	Activity
7	9/1/2021	Bromberg, Brian	0.6	Discuss cost savings reporting per plan with team.
7	9/1/2021	Johnson, Ancy	0.6	Attend internal call with team to discuss status of cost savings report.
7	9/1/2021	Johnson, Ancy	1.4	Evaluate manufacturing and inventory data provided by the Debtors.
7	9/1/2021	Knaak, Meredith	1.4	Prepare summary slides outlining status of cost savings analysis for team.
7	9/1/2021	Shafer, Patterson	1.3	Review presentation summarizing status of cost savings analysis and report.
7	9/2/2021	Baron, Genevieve	1.4	Analyze consumer and product profitability data provided.
7	9/2/2021	Baron, Genevieve	1.6	Continue to analyze consumer and product profitability data provided.
7	9/2/2021	Johnson, Ancy	0.9	Draft updated outline for cost savings report.
7	9/2/2021	Shafer, Patterson	1.2	Review latest draft outline of cost savings report to provide comments.
7	9/3/2021	Baron, Genevieve	2.2	Analyze customer and product profitability data provided for Avrio.
7	9/3/2021	Baron, Genevieve	1.8	Continue to analyze customer and product profitability data provided for Avrio.
7	9/3/2021	Johnson, Ancy	0.6	Review initial analysis of customer and product profitability data to provide guidance.
7	9/7/2021	Baron, Genevieve	1.9	Prepare further analysis of customer and product profitability data to incorporate comments.
7	9/8/2021	Baron, Genevieve	2.1	Analyze customer and product profitability data for Rhodes.
7	9/9/2021	Knaak, Meredith	1.6	Review current draft outline of cost savings report and information received to understand next steps.
7	9/10/2021	Baron, Genevieve	2.3	Prepare summary of analysis of customer and product profitability data for Purdue.
7	9/13/2021	Johnson, Ancy	2.1	Draft slides on customer and product profitability data for inclusion in report.
7	9/13/2021	Knaak, Meredith	2.1	Reviewing financial documents and manufacturing documents.
7	9/14/2021	Baron, Genevieve	2.7	Analyze manufacturing and inventory data provided.
7	9/14/2021	Bromberg, Brian	0.9	Review cost savings files to understand information received.
7	9/14/2021	Diaz, Matthew	0.6	Review status of the cost savings analysis.
7	9/14/2021	Johnson, Ancy	1.9	Continue to build out customer and product profitability section of report.
7	9/14/2021	Knaak, Meredith	2.3	Analyze data provided by the Debtor for third party spend for branded opioids.
7	9/14/2021	Shafer, Patterson	1.0	Review current status of cost savings analysis to provide guidance to team.
7	9/15/2021	Baron, Genevieve	2.6	Analyze manufacturing and inventory data re: branded opioids.
7	9/15/2021	Baron, Genevieve	1.8	Continue to analyze manufacturing and inventory data re: branded opioids.
7	9/15/2021	Baron, Genevieve	0.6	Attend call with Alix to discuss cost savings report.
7	9/15/2021	Diaz, Matthew	1.7	Review latest cost analysis report.
7	9/15/2021	Diaz, Matthew	0.5	Participate in a call with Alix on the cost analysis report.
7	9/15/2021	Johnson, Ancy	1.2	Prepare analysis for report re: potential cost savings in manufacturing and inventory.
7	9/15/2021	Knaak, Meredith	0.9	Analyze third party spend data for Avrio.
7	9/15/2021	Shafer, Patterson	0.5	Attend call with Alix to discuss cost savings analysis.
7	9/15/2021	Shafer, Patterson	1.8	Review data provided and status of cost savings analysis to evaluate next steps.
7	9/16/2021	Baron, Genevieve	2.2	Analyze manufacturing and inventory data re: Avrio.
7	9/16/2021	Baron, Genevieve	1.8	Continue to analyze manufacturing and inventory data re: Avrio.
7	9/16/2021	Johnson, Ancy	0.8	Review analysis of manufacturing and inventory data to provide guidance.
7	9/16/2021	Knaak, Meredith	3.4	Prepare analysis of Adlon and SVC Pharma cost calculations.
7	9/17/2021	Baron, Genevieve	2.3	Analyze manufacturing and inventory data for Adlon.
7	9/17/2021	Baron, Genevieve	2.7	Continue to analyze manufacturing and inventory data for Adlon.
7	9/17/2021	Johnson, Ancy	2.8	Prepare slides for cost savings report re: manufacturing data.
7	9/17/2021	Knaak, Meredith	2.2	Prepare analysis of Adlon costs for 2019 through 2021.
7	9/17/2021	Knaak, Meredith	1.9	Continue to prepare analysis of Adlon costs for 2019 through 2021.
7	9/17/2021	Shafer, Patterson	1.2	Review progress of cost savings analysis to provide guidance to team.
7	9/20/2021	Baron, Genevieve	2.1	Evaluate manufacturing and inventory data for Rhodes.
7	9/20/2021	Baron, Genevieve	2.4	Continue to evaluate manufacturing and inventory data for Rhodes.
7	9/20/2021	Johnson, Ancy	2.3	Draft slides to include in cost savings report summarizing initial findings.
7	9/20/2021	Johnson, Ancy	1.9	Continue to draft slides to include in cost savings report summarizing initial findings.
7	9/20/2021	Knaak, Meredith	3.1	Draft initial slides re: analysis of Adlon costs.
7	9/20/2021	Knaak, Meredith	1.3	Continue to prepare analysis of Adlon costs and spending.
7	9/20/2021	Shafer, Patterson	1.1	Review draft of cost savings report to provide guidance to team.
7	9/20/2021	Shafer, Patterson	0.9	Draft list for Alix re: interview requests.
7	9/21/2021	Baron, Genevieve	2.8	Analyze historical branded opioid costs data.
7	9/21/2021	Baron, Genevieve	2.2	Continue to analyze historical branded opioid costs data.
7	9/21/2021	Bromberg, Brian	0.7	Attend internal call to cost saving report.
7	9/21/2021	Diaz, Matthew	1.2	Review the company's cost savings analysis.
7	9/21/2021	Johnson, Ancy	3.3	Prepare draft presentation re: potential cost savings.
7	9/21/2021	Johnson, Ancy	0.7	Attend internal call to discuss progress of cost savings analysis.

EXHIBIT C

PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649

DETAIL OF TIME ENTRIES

FOR THE PERIOD SEPTEMBER 1, 2021 TO SEPTEMBER 30, 2021

Task Category	Date	Professional	Hours	Activity
7	9/21/2021	Knaak, Meredith	1.6	Prepare analysis and accompanying slides re: Adlon historical costs.
7	9/21/2021	Shafer, Patterson	0.7	Participate in internal call to share update on status of cost savings report.
7	9/21/2021	Shafer, Patterson	0.8	Provide comments to team on revised outline of cost savings report and initial findings.
7	9/22/2021	Baron, Genevieve	1.6	Draft initial slides in outline of cost savings report re: branded opioids.
7	9/22/2021	Baron, Genevieve	2.4	Continue to analyze historical cost data provided re: branded opioids.
7	9/22/2021	Diaz, Matthew	0.6	Review team's cost savings analysis.
7	9/22/2021	Johnson, Ancy	2.8	Prepare revisions to outline of cost savings report to incorporate initial analyses.
7	9/22/2021	Knaak, Meredith	1.4	Evaluate historical cost data provided re: Rhodes.
7	9/22/2021	Shafer, Patterson	0.6	Review updated outline of report to provide comments.
7	9/23/2021	Baron, Genevieve	2.4	Evaluate third party spend data provided for Purdue re: branded opioids.
7	9/23/2021	Baron, Genevieve	2.7	Continue to evaluate third party spend data provided for Purdue re: branded opioids.
7	9/23/2021	Baron, Genevieve	2.4	Evaluate third party spend data provided for Rhodes.
7	9/23/2021	Johnson, Ancy	3.2	Update draft cost savings report to reflect additional analyses.
7	9/23/2021	Knaak, Meredith	1.7	Prepare revisions to summary charts re: Adlon costs per internal comments.
7	9/23/2021	Shafer, Patterson	1.3	Review updated draft analyses and slides to provide comments.
7	9/24/2021	Baron, Genevieve	2.6	Analyze third party spend data for Avrio.
7	9/24/2021	Baron, Genevieve	2.4	Prepare summary charts re: analysis of third party spend data for Purdue.
7	9/24/2021	Johnson, Ancy	2.6	Incorporate additional analysis prepared by team into draft cost savings report.
7	9/24/2021	Shafer, Patterson	1.6	Review cost data provided and status of analysis to provide guidance to team re: next steps.
7	9/27/2021	Baron, Genevieve	2.8	Prepare initial summary charts re: analysis of third party spend data for Rhodes.
7	9/27/2021	Johnson, Ancy	0.9	Prepare updated outstanding diligence request list to prepare for call with Alix.
7	9/27/2021	Johnson, Ancy	0.5	Attend call with Alix to discuss cost savings analysis.
7	9/27/2021	Knaak, Meredith	1.7	Analyze manufacturing cost data files provided for Purdue.
7	9/27/2021	Shafer, Patterson	1.6	Review draft cost savings report to provide comments.
7	9/27/2021	Shafer, Patterson	0.5	Attend call with Alix to discuss cost savings analysis and outstanding requests.
7	9/28/2021	Baron, Genevieve	2.2	Prepare draft analyses of third party spend costs to include in report.
7	9/28/2021	Bromberg, Brian	0.5	Review cost savings report issues.
7	9/28/2021	Diaz, Matthew	0.4	Review update re: cost savings analysis.
7	9/28/2021	Johnson, Ancy	1.2	Continue to build out draft of the cost savings report.
7	9/28/2021	Knaak, Meredith	0.5	Continue to evaluate manufacturing data provided re: historical costs.
7	9/28/2021	Shafer, Patterson	1.1	Review status of diligence requests and identify potential follow ups.
7	9/29/2021	Baron, Genevieve	2.2	Continue to perform diligence analysis of cost files.
7	9/29/2021	Johnson, Ancy	0.5	Attend call with Alix to discuss cost savings analysis.
7	9/29/2021	Knaak, Meredith	0.5	Participate in call with Alix to discuss cost saving report.
7	9/29/2021	Shafer, Patterson	0.5	Attend call with Alix to discuss cost savings report status.
7	9/30/2021	Baron, Genevieve	2.1	Prepare summary of initial findings of cost savings data review.
7	9/30/2021	Baron, Genevieve	1.7	Continue to prepare summary of initial findings of cost savings data review.
7	9/30/2021	Johnson, Ancy	2.2	Review analyses prepared by team to provide guidance for next steps.
7	9/30/2021	Johnson, Ancy	2.1	Continue to build out draft cost savings report to incorporate additional analysis.
7	9/30/2021	Knaak, Meredith	0.9	Prepare summary of initial findings of manufacturing costs review.
7	9/30/2021	Shafer, Patterson	1.8	Review latest draft of cost savings report to evaluate outline and initial findings.
7 Total			162.2	
9	9/9/2021	Diaz, Matthew	0.9	Review Debtors' KEIP reply.
9	9/10/2021	Diaz, Matthew	0.4	Review Debtors' response on the objections to the KEIP.
9 Total			1.3	
10	9/1/2021	Joffe, Steven	0.5	Attend weekly AHC call to discuss case events, with a focus on tax matters.
10 Total			0.5	
11	9/1/2021	Bromberg, Brian	2.9	Attend virtual confirmation hearing.
11	9/1/2021	Simms, Steven	2.8	Attend confirmation hearing to evaluate case issues.
11	9/1/2021	Simms, Steven	2.3	Continue to attend confirmation hearing to evaluate case issues.
11	9/13/2021	Diaz, Matthew	2.7	Attend the Purdue hearing on the trust prepayments and the KEIP.
11 Total			10.7	
16	9/1/2021	Bromberg, Brian	0.5	Discuss excess cash with the Debtors.
16	9/1/2021	Bromberg, Brian	0.7	Review latest excess cash estimates to prepare for call.
16	9/1/2021	Diaz, Matthew	0.4	Participate in a call with Alix to discuss certain Sackler settlement agreement issues.
16	9/1/2021	Kurtz, Emma	0.3	Review latest excess cash estimates and materials.
16	9/2/2021	Diaz, Matthew	1.1	Review of confirmation hearing summaries and related next steps.
16	9/7/2021	Bromberg, Brian	1.6	Review filed disclosure statement and supplement.

EXHIBIT C

PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649

DETAIL OF TIME ENTRIES

FOR THE PERIOD SEPTEMBER 1, 2021 TO SEPTEMBER 30, 2021

Task Category	Date	Professional	Hours	Activity
16	9/8/2021	Diaz, Matthew	2.2	Review the updated 8/31 shareholder settlement agreement to evaluate changes.
16	9/14/2021	Bromberg, Brian	2.3	Review revisions to settlement agreement to understand changes.
16	9/14/2021	Diaz, Matthew	0.5	Participate in a call with Counsel to discuss IP transfer.
16	9/15/2021	Kurtz, Emma	0.8	Draft summary for Counsel identifying contracts requested additional information on to identify potential contracts to reject.
16	9/15/2021	Simms, Steven	0.2	Review latest status of settlement agreement.
16	9/20/2021	Diaz, Matthew	1.4	Review of the settlement agreement to evaluate changes.
16	9/20/2021	Simms, Steven	0.4	Review latest status of NewCo transfer agreement.
16	9/21/2021	Diaz, Matthew	0.6	Review the updated NewCo transfer agreement.
16	9/21/2021	Diaz, Matthew	0.3	Review Counsel's summaries on the appeal process and related next steps.
16	9/22/2021	Simms, Steven	0.6	Review information provided by Counsel re: appeals process.
16	9/24/2021	Diaz, Matthew	0.4	Review lease assumption and rejection schedule.
16	9/27/2021	Simms, Steven	0.6	Review update from team re: status of plan items.
16 Total			14.9	
19	9/8/2021	Diaz, Matthew	0.8	Review open items and related next steps.
19	9/8/2021	Simms, Steven	0.4	Review latest case workplan to understand next steps.
19	9/29/2021	Simms, Steven	0.4	Review ongoing case issues and understand next steps.
19 Total			1.6	
21	9/1/2021	Bromberg, Brian	0.5	Participate in weekly Committee call to discuss case updates.
21	9/2/2021	Bromberg, Brian	0.3	Participate in weekly corporate call to discuss emergence preparation.
21 Total			0.8	
22	9/10/2021	Diaz, Matthew	0.5	Participate in call with the monitor.
22 Total			0.5	
24	9/2/2021	Kurtz, Emma	1.7	Finish preparing draft July fee statement.
24	9/8/2021	Kurtz, Emma	0.4	Prepare revisions to June fee application to finalize for filing.
24	9/9/2021	Diaz, Matthew	1.1	Review July fee application.
24	9/10/2021	Hellmund-Mora, Marili	0.5	Update and finalize the June fee application.
24	9/10/2021	Kurtz, Emma	0.8	Prepare revisions to draft July fee application.
24	9/14/2021	Kurtz, Emma	2.8	Begin to prepare August fee application per bankruptcy guidelines.
24	9/16/2021	Kurtz, Emma	2.4	Continue to prepare draft August fee application.
24	9/22/2021	Diaz, Matthew	1.2	Review August fee application.
24	9/23/2021	Hellmund-Mora, Marili	0.5	Update and finalize the July fee application.
24	9/23/2021	Kurtz, Emma	0.6	Prepare revisions to August fee application.
24 Total			12.0	
26	9/1/2021	Diaz, Matthew	0.9	Review plan effective date and go forward insurance issues.
26	9/9/2021	Bromberg, Brian	0.6	Review insurance information for NewCo.
26	9/10/2021	Simms, Steven	0.3	Review update on NewCo insurance information.
26	9/14/2021	Diaz, Matthew	0.6	Review insurance analysis.
26	9/14/2021	Whitman, Andrew	0.3	Review update on latest insurance issues.
26	9/15/2021	Bromberg, Brian	0.7	Discuss insurance for NewCo and TopCo with Debtors.
26	9/15/2021	Bromberg, Brian	0.9	Review NewCo insurance presentation.
26	9/15/2021	Diaz, Matthew	0.5	Participate in a call with the company on the go forward insurance needs.
26	9/15/2021	Diaz, Matthew	0.6	Review Debtors' insurance presentation to prepare for the call with the Debtors.
26	9/15/2021	Simms, Steven	0.3	Review go forward insurance items for NewCo.
26	9/15/2021	Whitman, Andrew	0.8	Attend insurance update call with Debtors.
26	9/27/2021	Diaz, Matthew	0.6	Review of the Debtors' general liability insurance analysis.
26	9/27/2021	Whitman, Andrew	0.1	Review email correspondence related to insurance issues.
26 Total			7.2	
30	9/8/2021	Bromberg, Brian	1.7	Draft outline of outstanding workstreams, with a focus on emergence preparation.
30	9/8/2021	Bromberg, Brian	0.7	Discuss emergence preparation workstreams with team.
30	9/8/2021	Kurtz, Emma	0.6	Discuss internally re: case workstreams and upcoming deliverables in preparation for emergence.
30	9/8/2021	Turner, Ian	0.5	Attend internal call to discuss emergence preparation workstreams.
30	9/10/2021	Diaz, Matthew	0.5	Participate in call with counsel to discuss NewCo emergence issues.
30	9/10/2021	Diaz, Matthew	1.0	Participate in call with Houlihan to discuss post emergence structures.
30	9/13/2021	Bromberg, Brian	0.9	Review latest emergence workstreams summary and checklist.
30	9/13/2021	Diaz, Matthew	1.1	Perform detailed review of the Purdue emergence work plan and checklist.
30	9/13/2021	Kurtz, Emma	0.8	Draft updated summary of emergence workstreams outline.
30	9/13/2021	Simms, Steven	0.8	Evaluate post confirmation items and workplan.

EXHIBIT C

PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649

DETAIL OF TIME ENTRIES

FOR THE PERIOD SEPTEMBER 1, 2021 TO SEPTEMBER 30, 2021

Task Category	Date	Professional	Hours	Activity
30	9/14/2021	Bromberg, Brian	0.8	Attend call with team to discuss outstanding NewCo transfers workstreams.
30	9/14/2021	Bromberg, Brian	1.3	Review latest outline of emergence workstreams to prepare for calls.
30	9/14/2021	Bromberg, Brian	0.6	Discuss IP and transfer to NewCo with counsel.
30	9/14/2021	Bromberg, Brian	0.8	Compile license agreements to share with Counsel.
30	9/14/2021	Bromberg, Brian	0.8	Prepare follow up questions for AlixPartners re: emergence preparation.
30	9/14/2021	Diaz, Matthew	0.9	Review emergence next steps and workplan.
30	9/14/2021	Diaz, Matthew	0.7	Develop settlement agreement section outline to include in NewCo board book.
30	9/14/2021	Kurtz, Emma	0.7	Attend call with team to discuss NewCo transfers workstreams and next steps.
30	9/14/2021	Kurtz, Emma	1.3	Prepare draft workplan and tracker for NewCo transfer workstreams and board book materials.
30	9/14/2021	Simms, Steven	0.5	Review latest summary of emergence preparation workstreams.
30	9/14/2021	Turner, Ian	0.7	Attend call with internal team to discuss NewCo board book and transfers workstreams.
30	9/15/2021	Bromberg, Brian	0.5	Draft follow-up questions for Alix re: emergence preparation.
30	9/15/2021	Bromberg, Brian	2.2	Draft outline of MDT Board book.
30	9/15/2021	Bromberg, Brian	0.6	Discuss MDT Board Book with counsel.
30	9/15/2021	Diaz, Matthew	1.1	Review next steps on outline for MDT board book.
30	9/15/2021	Diaz, Matthew	0.5	Participate in call with Counsel to discuss the MDT board book.
30	9/15/2021	Kurtz, Emma	0.8	Prepare revisions to NewCo board book slides to reflect internal comments
30	9/15/2021	Kurtz, Emma	1.3	Draft summary slides of key prepetition contracts and related analyses to include in NewCo board book.
30	9/15/2021	Kurtz, Emma	1.7	Prepare analysis of largest vendor spend by prepetition contract counter-party to be included in NewCo board book.
30	9/15/2021	Kurtz, Emma	1.4	Prepare revisions to 2021 KEIP KERP slides to reflect final plans to be included in NewCo board book.
30	9/15/2021	Kurtz, Emma	2.2	Prepare draft outline of presentation to the MDT board.
30	9/15/2021	Turner, Ian	0.5	Attend call with Counsel to discuss MDT board book and next steps.
30	9/16/2021	Bromberg, Brian	1.9	Prepare revisions to draft outline of MDT board book presentation.
30	9/17/2021	Bromberg, Brian	0.6	Follow up on questions to Alix re: emergence preparation.
30	9/17/2021	Bromberg, Brian	2.6	Draft initial slides in outline of MDT Board book and identify next steps.
30	9/17/2021	Diaz, Matthew	1.5	Review of the settlement agreement in connection with preparing the MDT board presentation.
30	9/17/2021	Kurtz, Emma	0.7	Prepare revisions to outline of MDT board book presentation.
30	9/17/2021	Kurtz, Emma	2.1	Prepare additional draft slides for MDT board book outline to reflect internal comments.
30	9/17/2021	Kurtz, Emma	1.3	Review IAC overview slides for section of MDT board book.
30	9/20/2021	Bromberg, Brian	1.2	Review and respond to questions from Counsel on NewCo transfer agreement.
30	9/20/2021	Bromberg, Brian	1.4	Review task list re: NewCo transfer workstreams and progress.
30	9/20/2021	Bromberg, Brian	1.3	Finalize MDT board deck draft outline to share with Counsel.
30	9/20/2021	Bromberg, Brian	0.6	Discuss MDT board book outline with Counsel.
30	9/20/2021	Bromberg, Brian	0.8	Prepare revisions to draft outline for MDT board book per call with Counsel.
30	9/20/2021	Bromberg, Brian	1.5	Review NewCo board book slides to provide comments.
30	9/20/2021	Diaz, Matthew	0.8	Review NewCo Board briefing book and related next steps.
30	9/20/2021	Diaz, Matthew	1.6	Conduct detailed review of the MDT board book outline.
30	9/20/2021	Diaz, Matthew	0.5	Participate in call with Counsel to discuss the MDT board book.
30	9/20/2021	Kurtz, Emma	1.4	Prepare analysis of employee census to summarize key employee metrics for NewCo Board Book.
30	9/20/2021	Kurtz, Emma	1.1	Prepare revisions to employee metrics summary slide in NewCo Board Book per internal comments.
30	9/20/2021	Turner, Ian	2.1	Review employee wages first day motion to draft employee benefits slides for NewCo transfer presentation.
30	9/20/2021	Turner, Ian	2.8	Prepare analysis of employee benefit programs to include in NewCo board book.
30	9/20/2021	Turner, Ian	0.5	Discuss MDT Board Book with Counsel.
30	9/20/2021	Turner, Ian	1.6	Prepare revisions to employee benefit slides in NewCo board book per internal comments.
30	9/21/2021	Bromberg, Brian	1.1	Review progress on workstreams on MDT book.
30	9/21/2021	Bromberg, Brian	2.1	Review Settlement Agreement to include summary in MDT book.
30	9/21/2021	Bromberg, Brian	0.9	Discuss internally re: workplan for preparing MDT board book.
30	9/21/2021	Bromberg, Brian	1.8	Review Settlement Agreement reporting required.
30	9/21/2021	Kurtz, Emma	1.3	Prepare revisions to draft outline of the MDT board book presentation per discussion with KL.
30	9/21/2021	Kurtz, Emma	1.9	Prepare revisions to MDT board book outline per internal comments.

Pg 14 of 15

EXHIBIT C

PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649

DETAIL OF TIME ENTRIES

FOR THE PERIOD SEPTEMBER 1, 2021 TO SEPTEMBER 30, 2021

Task Category	Date	Professional	Hours	Activity
30	9/21/2021	Kurtz, Emma	3.1	Prepare IAC overview section of MDT board book.
30	9/21/2021	Kurtz, Emma	2.2	Prepare analysis of IAC sales by product and various IAC functions to include in MDT board book.
30	9/21/2021	Kurtz, Emma	1.3	Draft A-Side covenants and A-Side reporting section per the Sackler settlement agreement to include in MDT board book.
30	9/21/2021	Kurtz, Emma	2.2	Update analysis of A-Side and B-Side credit support to reflect latest asset values to include in MDT board book.
30	9/21/2021	Turner, Ian	0.9	Attend call with team to discuss MDT board book outline and next steps.
30	9/21/2021	Turner, Ian	1.9	Prepare settlement agreement calendar and time line of payments summary slides for MDT board.
30	9/21/2021	Turner, Ian	3.1	Prepare settlement agreement payment mechanics overview slides to include in the MDT board book.
30	9/22/2021	Bromberg, Brian	3.2	Provide comments on MDT Board deck settlement agreement payment mechanics section.
30	9/22/2021	Bromberg, Brian	1.9	Review credit support, covenants, and IAC overview sections of the MDT board book.
30	9/22/2021	Kurtz, Emma	1.9	Prepare reporting overview section of the MDT board book re: summary of reporting required under the settlement agreement and credit support agreements.
30	9/22/2021	Kurtz, Emma	2.6	Draft slides re: B-side covenants and B-side required reporting per B-side credit support agreement for MDT board book.
30	9/22/2021	Kurtz, Emma	1.4	Update analysis of distributions from the MDT and private settlements to include in MDT board book.
30	9/22/2021	Kurtz, Emma	1.7	Prepare revisions to draft MDT board book slides per internal comments.
30	9/22/2021	Turner, Ian	1.8	Draft MDT board book slides for calendar of reporting, appeals process, and payment mechanics.
30	9/22/2021	Turner, Ian	1.2	Prepare revisions to MDT board book slides re: payment mechanics per internal comments.
30	9/22/2021	Turner, Ian	2.7	Draft slides for MDT board book re: settlement agreement payment mechanics illustrative examples.
30	9/22/2021	Turner, Ian	2.4	Prepare revisions to MDT board book slides, including appeals process and payment mechanics walk through.
30	9/23/2021	Bromberg, Brian	1.7	Review NewCo transfer workstreams and status.
30	9/23/2021	Bromberg, Brian	0.9	Discuss NewCo transfer workstreams with Houlihan.
30	9/23/2021	Bromberg, Brian	0.5	Discuss corporate workstreams with counsel re: emergence preparation.
30	9/23/2021	Bromberg, Brian	0.4	Prepare summary of calls with Houlihan and Counsel re: NewCo transfer workstreams for team.
30	9/23/2021	Bromberg, Brian	0.8	Discuss NewCo transfer workstreams with Counsel.
30	9/23/2021	Bromberg, Brian	0.6	Review updated draft of MDT board book.
30	9/23/2021	Diaz, Matthew	0.8	Participate in call with Counsel to discuss the emergence check list.
30	9/23/2021	Diaz, Matthew	1.6	Review draft MDT presentation outline to prepare revisions.
30	9/23/2021	Kurtz, Emma	0.8	Attend call with Counsel to discuss status of workstreams related to NewCo transfers.
30	9/23/2021	Turner, Ian	0.6	Prepare further revisions to draft MDT board book payment mechanics section per internal comments.
30	9/24/2021	Bromberg, Brian	1.9	Review latest draft of MDT board book to provide comments.
30	9/24/2021	Bromberg, Brian	1.5	Finalize and send draft of MDT deck.
30	9/24/2021	Bromberg, Brian	1.1	Draft update on status of NewCo workstreams.
30	9/24/2021	Diaz, Matthew	2.7	Review draft MDT board book to provide comments.
30	9/24/2021	Turner, Ian	0.4	Prepare revisions to calendar of payments slide in MDT board book.
30	9/27/2021	Bromberg, Brian	0.7	Review NewCo board book slides to provide comments to team.
30	9/27/2021	Bromberg, Brian	1.1	Review updated MDT board book slides to provide comments.
30	9/27/2021	Diaz, Matthew	1.6	Review MDT board book re: settlement agreement section.
30	9/27/2021	Kurtz, Emma	1.2	Prepare summary of A-side and B-side reporting required under CSAs and timing to be included in MDT board book.
30	9/27/2021	Turner, Ian	1.5	Prepare summary of required reporting to the MDT under the plan and settlement agreement.
30	9/28/2021	Bromberg, Brian	0.9	Provide comments to team on NewCo board book slides.
30	9/28/2021	Bromberg, Brian	0.3	Review requests to Debtors re: emergence workstreams.
30	9/28/2021	Bromberg, Brian	0.6	Review Sackler Asset presentations to evaluate additional information to include in MDT board book.
30	9/28/2021	Bromberg, Brian	0.8	Review revisions to NOAT cash flows based on latest estimates.
30	9/28/2021	Diaz, Matthew	0.7	Review employee slides for the NewCo board book.

EXHIBIT C

PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649

DETAIL OF TIME ENTRIES

FOR THE PERIOD SEPTEMBER 1, 2021 TO SEPTEMBER 30, 2021

Task Category	Date	Professional	Hours	Activity
30	9/28/2021	Kurtz, Emma	0.3	Prepare revisions to NOAT cash flows included in MDT board book per internal comments.
30	9/28/2021	Kurtz, Emma	2.1	Prepare revisions to NewCo board book re: employee programs and census per internal comments.
30	9/28/2021	Turner, Ian	1.6	Prepare revisions to settlement agreement section of MDT board book per internal comments.
30	9/29/2021	Bromberg, Brian	1.6	Review updated draft MDT book to evaluate changes.
30	9/29/2021	Diaz, Matthew	1.2	Continue to review MDT board book settlement agreement section.
30	9/29/2021	Turner, Ian	0.2	Prepare updates to MDT book reporting calendar summary slide to reflect internal feedback.
30	9/30/2021	Diaz, Matthew	3.1	Review revised draft of the MDT board book.
30	9/30/2021	Diaz, Matthew	1.6	Review shareholder settlement agreement to evaluate summary included in MDT board book.
30	9/30/2021	Kurtz, Emma	2.1	Prepare revisions to summary analysis of A-side and B-side asset values included in MDT board book to reflect latest asset reports.
30	9/30/2021	Turner, Ian	2.7	Prepare additional payment mechanic scenario slides for MDT presentation.
30 Total			147.2	
Grand Total			374.2	